Condition: Mitral Regurgitation · Sponsor: HighLife SAS
to evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.
This description comes directly from the study's public registry record.
Martin Rothman, MD · +1 707 2177167 · MRothman@highlifemed.com
Always discuss trial participation with your own doctor first.
| St. Vincent's Hospital - Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| John Hunter Hospital | Newcastle, New South Wales, Australia | Recruiting |
| Macquarie University Hospital | Sydney, New South Wales, Australia | Withdrawn |
| The Wesley Hospital | Auchenflower, Queensland, Australia | Recruiting |
| St. Andrew's Hospital | Adelaide, Australia | Recruiting |
| Princess Alexandra Hospital | Brisbane, Australia | Recruiting |
| Warringal Hospital | Heidelberg, Australia | Terminated |
| The Alfred Hospital | Melbourne, Australia | Recruiting |
| John Hunter Hospital | Newcastle, Australia | Recruiting |
| Mount Hospital | Perth, Australia | Recruiting |
| North Shore Private Hospital | Sydney, Australia | Recruiting |
| ZNA Middelheim | Antwerp, Belgium | Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04029363